- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07510906
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer (P-PET)
A Pilot Study to Evaluate the Imaging Capability of a Novel Prostate-targeted PET System (P-PET) to Detect Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pilot study will evaluate the performance of a novel prostate-targeted positron emission tomography (PET) imaging system (P-PET) in men undergoing PET imaging for primary staging of prostate cancer. This study is designed to assess the feasibility and diagnostic performance of this new imaging approach.
Participants will receive the standard-of-care PET radiotracer fluroine-18 PSMA-1007 (18F-PSMA-1007) as part of routine clinical PET imaging. While the tracer is circulating in the body, a research dynamic imaging sequence will be performed, followed by the standard-of-care whole body PET scan. Immediately after completion of the standard imaging, participants will undergo the research P-PET scan during the same imaging visit. No additional radiotracer will be administered for the P-PET scan, as it used the same tracer injection given for the standard-of-care PET imaging.
Images obtained from the P-PET system will undergo comparative analysis with the standard-of-care PET scan images to assess lesion detection, image quality and overall imaging performance. The findings from this study will provide preliminary data on feasibility and potential diagnostic value of the P-PET system and may guide future research in prostate-targeted PET imaging.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maureen Dougan
- Phone Number: 35352 519-685-8300
- Email: maureen.dougan@sjhc.london.on.ca
Study Contact Backup
- Name: Stephen Pautler, BSc MD FRCSC
- Phone Number: ext. 66384 519-646-6100
- Email: Stephen.Pautler@sjhc.london.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- St. Joseph Health Care London
-
Contact:
- Maureen Dougan
- Phone Number: 35352 519-685-8300
- Email: maureen.dougan@sjhc.london.on.ca
-
Contact:
- Anna MacDonald
- Phone Number: 35352 519-685-8300
- Email: anna.macdonald@sjhc.london.on.ca
-
Principal Investigator:
- Stephan Pautler, BSc MD FRCSC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Qualitative comparison of PET scans acquired by the P-PET vs. WB PET
Exclusion Criteria:
- Unable to comply with the length of scan time due to the study imaging.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Standard-of-care PET Scan with Additional Dynamic and P-PET imaging.
This is a prospective, single-arm, pilot diagnostic study to evaluate the diagnostic study to evaluate the diagnostic accuracy of using dynamic PET, and P-PET in 25 patients with biopsy proven prostate cancer.
This study will take place during the scheduled routine clinical PSMA PET/CT scan.
|
Participants will undergo a prostate-targeted PET scan to detect prostate cancer.
This research scan is performed after the standard-of-care PET scan to evaluate its imaging capability.
While the radioisotope is still active.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative comparison of PET scans acquired by the P-PET vs. WB PET
Time Frame: Baseline (Day1)
|
The primary outcome is the detection of prostate cancer lesions by the research prostate-targeted P-PET scan.
Images from the P-PET scan will be compared to standard-of-care PET scan images to evaluate the sensitivity and clarity of the new imaging system in identifying cancerous lesions in the prostate.
|
Baseline (Day1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Prostate Lesions Detected by P-PET Compared with Standard-of-care Whole-Body PET
Time Frame: Baseline (Day 1)
|
The number of pelvic lesions detected by P-PET in comparison with the number of lesions detected by standard-of-care whole body PET/CT.
|
Baseline (Day 1)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen Pautler, BSc MD FRCSC, St. Joseph Health Care London
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Washington University School of MedicineThe Society of Nuclear Medicine and Molecular ImagingNot yet recruitingRecurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer MetastaticUnited States
Clinical Trials on Prostate-Targeted PET- Scan (P-PET).
-
Peter MacCallum Cancer Centre, AustraliaSt Vincent's Hospital, SydneyActive, not recruitingProstate CancerAustralia
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Emory UniversityNational Cancer Institute (NCI)Completed
-
Centre Henri BecquerelCompletedNon-small Cell Lung CancerFrance
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingProstate Cancer Screening | PSMA-PETChina
-
Jeremy KoppelNational Institute of Mental Health (NIMH)RecruitingLate Onset Schizophrenia | Delusional Disorder (Late Onset)United States
-
University of Texas Southwestern Medical CenterCompletedTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
University of OklahomaMidwest Medical IsotopesTerminatedNon-Hodgkin's LymphomaUnited States
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States